Considering Pacira Biosciences Inc (PCRX) Stock After Q1 Report? Check the Details
Pacira Biosciences (PCRX) reported Q1 2026 results on April 30: revenue rose 5% YoY to $177.4M, above the $172.46M projection. Exparel sales volume increased 7% and accounted for over 80% of revenue. GAAP net income was $2.9M vs. $4.8M prior year; cash totaled $202.2M and $50M was spent on buybacks. Full-year revenue guidance is $745M–$770M, with Exparel $600M–$620M.
How this was made
The 30-second read
Why it matters
The article frames the stock as investable after Q1 by highlighting a revenue beat, Exparel volume growth, cash position, buybacks, and explicit FY 2026 revenue/Exparel ranges; it also reiterates the expected end-2026 topline readout for ASCEND.
Market read
Traders can update positioning based on the provided Q1 beat and the FY 2026 revenue/Exparel guidance ranges, plus the next major catalyst window for PCRX-201.
What to watch
Exparel remains >80% of revenue; any demand or pricing pressure could dominate despite pipeline optionality.
Background
Pacira is a specialty pharma focused on non-opioid pain management, with Exparel as its flagship product and PCRX-201 (gene therapy for knee osteoarthritis) in Phase 2.
Ticker impact
Pacira reported Q1 2026 results and issued 2026 revenue/Exparel guidance plus Phase 2 ASCEND topline timing for PCRX-201.
Potentially bullish bias for PCRX as traders re-rate on beat + raised/confirmed outlook; follow-through depends on Q2 execution and Exparel demand durability.
The article provides concrete Q1 datapoints (revenue beat, Exparel volume +7%), cash/buyback activity, and explicit FY 2026 revenue and Exparel sales ranges, which typically drive post-earnings positioning.
Market effects
Reinforces read-through that non-opioid pain management and commercial execution in specialty pharma can sustain investor appetite.
Limited; primarily US small/mid-cap biotech sentiment.
Low; no cross-border deal/regulatory catalyst mentioned.
Counterpoint
GAAP net income declined YoY due to higher research expenses, so upside may be more execution-driven than profitability-driven.
Key entities
- companyPacira Biosciences Inc
Reported Q1 2026 results, provided FY 2026 revenue and Exparel sales guidance, and discussed Phase 2 ASCEND topline timing for PCRX-201.
- productExparel
Flagship product; article cites +7% Exparel sales volume and FY 2026 Exparel sales projection of $600M–$620M.
- pipeline_programPCRX-201 / Phase 2 ASCEND
Gene therapy for knee osteoarthritis; topline data expected by end of 2026.
